Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Vanessa Dubois, Jérôme Eeckhoute, Philippe Lefebvre, and Bart Staels
University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Address correspondence to: Bart Staels, Institut Pasteur de Lille, 1 rue du Professeur Calmette, 59019 Lille, France. Phone: 33.3.20.87.78.25; E-mail: bart.staels@pasteur-lille.fr.
Find articles by Dubois, V. in: JCI | PubMed | Google Scholar
University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Address correspondence to: Bart Staels, Institut Pasteur de Lille, 1 rue du Professeur Calmette, 59019 Lille, France. Phone: 33.3.20.87.78.25; E-mail: bart.staels@pasteur-lille.fr.
Find articles by Eeckhoute, J. in: JCI | PubMed | Google Scholar
University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Address correspondence to: Bart Staels, Institut Pasteur de Lille, 1 rue du Professeur Calmette, 59019 Lille, France. Phone: 33.3.20.87.78.25; E-mail: bart.staels@pasteur-lille.fr.
Find articles by Lefebvre, P. in: JCI | PubMed | Google Scholar
University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Address correspondence to: Bart Staels, Institut Pasteur de Lille, 1 rue du Professeur Calmette, 59019 Lille, France. Phone: 33.3.20.87.78.25; E-mail: bart.staels@pasteur-lille.fr.
Find articles by Staels, B. in: JCI | PubMed | Google Scholar
First published April 3, 2017 - More info
J Clin Invest. 2017;127(4):1202–1214. doi:10.1172/JCI88894.
Copyright © 2017, American Society for Clinical Investigation
Peroxisome proliferator–activated receptors (PPARs) regulate energy metabolism and hence are therapeutic targets in metabolic diseases such as type 2 diabetes and non-alcoholic fatty liver disease. While they share anti-inflammatory activities, the PPAR isotypes distinguish themselves by differential actions on lipid and glucose homeostasis. In this Review we discuss the complementary and distinct metabolic effects of the PPAR isotypes together with the underlying cellular and molecular mechanisms, as well as the synthetic PPAR ligands that are used in the clinic or under development. We highlight the potential of new PPAR ligands with improved efficacy and safety profiles in the treatment of complex metabolic disorders.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Print subscription
- $735
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2017 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)